Search

Your search keyword '"Duquette, Pierre"' showing total 786 results

Search Constraints

Start Over You searched for: Author "Duquette, Pierre" Remove constraint Author: "Duquette, Pierre"
786 results on '"Duquette, Pierre"'

Search Results

1. A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

3. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

4. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

6. Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease

8. Author Correction: A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

9. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis

10. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

12. Mémoire prospective, sclérose en plaques et vieillissement: évaluation dans un contexte familier comportant des intentions autogénérées et imposées.

13. Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study

14. CLMP Promotes Leukocyte Migration Across Brain Barriers in Multiple Sclerosis

15. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

16. Efficacy of cannabinoids compared to the current standard treatments on symptom relief in persons with multiple sclerosis (CANSEP trial): study protocol for a randomized clinical trial.

17. Emulating randomised clinical trials in relapsing)remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.

18. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

19. Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry

21. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

25. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy

27. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting

28. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

29. Effect of Disease Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years

30. Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.

31. Association of multiple sclerosis susceptibility variants and early attack location in the CNS.

32. CD70 defines a subset of proinflammatory and CNS-pathogenic TH1/TH17 lymphocytes and is overexpressed in multiple sclerosis

33. Inhibition of Glyceraldehyde-3-Phosphate Dehydrogenase Activity by Antibodies Present in the Cerebrospinal Fluid of Patients with Multiple Sclerosis

34. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

37. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

38. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

41. Effectiveness of multiple disease- modifying therapies in relapsing- remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial.

42. Risk of secondary progressive multiple sclerosis after early worsening of disability.

43. Interleukin-26, preferentially produced by TH17 lymphocytes, regulates CNS barrier function

44. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis

45. Disability accrual in primary and secondary progressive multiple sclerosis

46. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis

47. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

50. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

Catalog

Books, media, physical & digital resources